Cargando…

Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer

BACKGROUND: Multidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives 1–16 were obtained by derivatization of the macroc...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis, Mariana Alves, Matos, Ana M., Duarte, Noélia, Ahmed, Omar Bauomy, Ferreira, Ricardo J., Lage, Hermann, Ferreira, Maria-José U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226783/
https://www.ncbi.nlm.nih.gov/pubmed/32457612
http://dx.doi.org/10.3389/fphar.2020.00599
_version_ 1783534360953094144
author Reis, Mariana Alves
Matos, Ana M.
Duarte, Noélia
Ahmed, Omar Bauomy
Ferreira, Ricardo J.
Lage, Hermann
Ferreira, Maria-José U.
author_facet Reis, Mariana Alves
Matos, Ana M.
Duarte, Noélia
Ahmed, Omar Bauomy
Ferreira, Ricardo J.
Lage, Hermann
Ferreira, Maria-José U.
author_sort Reis, Mariana Alves
collection PubMed
description BACKGROUND: Multidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives 1–16 were obtained by derivatization of the macrocyclic diterpene epoxyboetirane A (17), a lathyrane-type macrocyclic diterpene isolated from Euphorbia boetica. Some of these compounds were found to strongly modulate P-glycoprotein (P-gp/ABCB1) efflux. PURPOSE: The main goal was to develop lathyrane-type macrocyclic diterpenes with improved MDR-modifying activity, by targeting more than one anti-MDR mechanism. STUDY DESIGN/METHODS: In this study, the potential CS effect of compounds 1–16 was evaluated against gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29) human cancer cells and their drug-resistant counterparts, respectively selected against mitoxantrone (EPG85-257RNOV; EPP85-181RNOV; HT-RNOV) or daunorubicin (EPG85-257RDB; EPP85-181RDB; HT-RDB). The most promising compounds (8, 15, and 16) were investigated as apoptosis inducers, using the assays annexin V/PI and active caspase-3. RESULTS: The compounds were more effective against the resistant gastric cell lines, being the CS effect more significant in EPG85-257RDB cells. Taking together the IC(50) values and the CS effect, compounds 8, 15, and 16 exhibited the best results. Epoxyboetirane P (8), with the strongest MDR-selective antiproliferative activity against gastric carcinoma EPG85-257RDB cells (IC(50) of 0.72 µM), being 10-fold more active against this resistant subline than in sensitive gastric carcinoma cells. The CS effect elicited by compounds 15 and 16 appeared to be by inducing apoptosis via caspase-3 activation. Structure-activity relationships of the compounds were additionally obtained through regression models to clarify the structural determinants associated to the CS effect. CONCLUSIONS: This study reinforces the importance of lathyrane-type diterpenes as lead molecules for the research of MDR-modifying agents.
format Online
Article
Text
id pubmed-7226783
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72267832020-05-25 Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer Reis, Mariana Alves Matos, Ana M. Duarte, Noélia Ahmed, Omar Bauomy Ferreira, Ricardo J. Lage, Hermann Ferreira, Maria-José U. Front Pharmacol Pharmacology BACKGROUND: Multidrug resistance (MDR) has been regarded as one of the major hurdles for the successful outcome of cancer chemotherapy. The collateral sensitivity (CS) effect is one the most auspicious anti-MDR strategies. Epoxylathyrane derivatives 1–16 were obtained by derivatization of the macrocyclic diterpene epoxyboetirane A (17), a lathyrane-type macrocyclic diterpene isolated from Euphorbia boetica. Some of these compounds were found to strongly modulate P-glycoprotein (P-gp/ABCB1) efflux. PURPOSE: The main goal was to develop lathyrane-type macrocyclic diterpenes with improved MDR-modifying activity, by targeting more than one anti-MDR mechanism. STUDY DESIGN/METHODS: In this study, the potential CS effect of compounds 1–16 was evaluated against gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29) human cancer cells and their drug-resistant counterparts, respectively selected against mitoxantrone (EPG85-257RNOV; EPP85-181RNOV; HT-RNOV) or daunorubicin (EPG85-257RDB; EPP85-181RDB; HT-RDB). The most promising compounds (8, 15, and 16) were investigated as apoptosis inducers, using the assays annexin V/PI and active caspase-3. RESULTS: The compounds were more effective against the resistant gastric cell lines, being the CS effect more significant in EPG85-257RDB cells. Taking together the IC(50) values and the CS effect, compounds 8, 15, and 16 exhibited the best results. Epoxyboetirane P (8), with the strongest MDR-selective antiproliferative activity against gastric carcinoma EPG85-257RDB cells (IC(50) of 0.72 µM), being 10-fold more active against this resistant subline than in sensitive gastric carcinoma cells. The CS effect elicited by compounds 15 and 16 appeared to be by inducing apoptosis via caspase-3 activation. Structure-activity relationships of the compounds were additionally obtained through regression models to clarify the structural determinants associated to the CS effect. CONCLUSIONS: This study reinforces the importance of lathyrane-type diterpenes as lead molecules for the research of MDR-modifying agents. Frontiers Media S.A. 2020-05-08 /pmc/articles/PMC7226783/ /pubmed/32457612 http://dx.doi.org/10.3389/fphar.2020.00599 Text en Copyright © 2020 Reis, Matos, Duarte, Ahmed, Ferreira, Lage and Ferreira http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Reis, Mariana Alves
Matos, Ana M.
Duarte, Noélia
Ahmed, Omar Bauomy
Ferreira, Ricardo J.
Lage, Hermann
Ferreira, Maria-José U.
Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
title Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
title_full Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
title_fullStr Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
title_full_unstemmed Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
title_short Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
title_sort epoxylathyrane derivatives as mdr-selective compounds for disabling multidrug resistance in cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226783/
https://www.ncbi.nlm.nih.gov/pubmed/32457612
http://dx.doi.org/10.3389/fphar.2020.00599
work_keys_str_mv AT reismarianaalves epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer
AT matosanam epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer
AT duartenoelia epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer
AT ahmedomarbauomy epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer
AT ferreiraricardoj epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer
AT lagehermann epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer
AT ferreiramariajoseu epoxylathyranederivativesasmdrselectivecompoundsfordisablingmultidrugresistanceincancer